King's College London

Research portal

Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study

Research output: Contribution to journalArticle

Standard

Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage : a randomised, double-masked, placebo-controlled feasibility study. / Petrarca, Robert; Soare, Cristina; Wong, Roger; Desai, Riti; Neffendorf, James; Simpson, Andrew; Jackson, Timothy L.

In: Acta Ophthalmologica, 01.11.2019.

Research output: Contribution to journalArticle

Harvard

Petrarca, R, Soare, C, Wong, R, Desai, R, Neffendorf, J, Simpson, A & Jackson, TL 2019, 'Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study', Acta Ophthalmologica. https://doi.org/10.1111/aos.14282

APA

Petrarca, R., Soare, C., Wong, R., Desai, R., Neffendorf, J., Simpson, A., & Jackson, T. L. (2019). Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study. Acta Ophthalmologica. https://doi.org/10.1111/aos.14282

Vancouver

Petrarca R, Soare C, Wong R, Desai R, Neffendorf J, Simpson A et al. Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study. Acta Ophthalmologica. 2019 Nov 1. https://doi.org/10.1111/aos.14282

Author

Petrarca, Robert ; Soare, Cristina ; Wong, Roger ; Desai, Riti ; Neffendorf, James ; Simpson, Andrew ; Jackson, Timothy L. / Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage : a randomised, double-masked, placebo-controlled feasibility study. In: Acta Ophthalmologica. 2019.

Bibtex Download

@article{7223a0e132fe4ca2afef675aa801dacd,
title = "Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study",
abstract = "PURPOSE: To determine the feasibility of a definitive study of intravitreal ranibizumab to promote the clearance of persistent diabetic vitreous haemorrhage and thereby avoid vitrectomy.METHODS: This randomised, double-masked, placebo-controlled feasibility study recruited 24 participants with persistent diabetic vitreous haemorrhage listed for pars plana vitrectomy. Participants were randomised to a single 0.5-mg intravitreal ranibizumab injection or a single subconjunctival saline injection. The primary outcome measure was the number of participants requiring pars plana vitrectomy at week 7.RESULTS: Eight of 12 participants (66.7{\%}) in the ranibizumab group required vitrectomy at week 7 versus 12 of 12 (100{\%}) in the placebo group (absolute risk reduction 33.3{\%}, 95{\%} confidence interval 2.1-70.7{\%}; p = 0.09). One additional eye in the ranibizumab group required vitrectomy by 12 months. Mean visual acuity letter score at 12 months was 72.7 ± 12.3 in the ranibizumab group and 75.1 ± 10.1 in the placebo group. Safety was similar across groups.CONCLUSION: Intravitreal ranibizumab may reduce the likelihood of proceeding to vitrectomy in patients with persistent, dense diabetic vitreous haemorrhage. Further studies appear feasible and justified.",
keywords = "diabetic vitreous haemorrhage, ranibizumab, vitrectomy",
author = "Robert Petrarca and Cristina Soare and Roger Wong and Riti Desai and James Neffendorf and Andrew Simpson and Jackson, {Timothy L}",
note = "{\circledC} 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.",
year = "2019",
month = "11",
day = "1",
doi = "10.1111/aos.14282",
language = "English",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage

T2 - a randomised, double-masked, placebo-controlled feasibility study

AU - Petrarca, Robert

AU - Soare, Cristina

AU - Wong, Roger

AU - Desai, Riti

AU - Neffendorf, James

AU - Simpson, Andrew

AU - Jackson, Timothy L

N1 - © 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - PURPOSE: To determine the feasibility of a definitive study of intravitreal ranibizumab to promote the clearance of persistent diabetic vitreous haemorrhage and thereby avoid vitrectomy.METHODS: This randomised, double-masked, placebo-controlled feasibility study recruited 24 participants with persistent diabetic vitreous haemorrhage listed for pars plana vitrectomy. Participants were randomised to a single 0.5-mg intravitreal ranibizumab injection or a single subconjunctival saline injection. The primary outcome measure was the number of participants requiring pars plana vitrectomy at week 7.RESULTS: Eight of 12 participants (66.7%) in the ranibizumab group required vitrectomy at week 7 versus 12 of 12 (100%) in the placebo group (absolute risk reduction 33.3%, 95% confidence interval 2.1-70.7%; p = 0.09). One additional eye in the ranibizumab group required vitrectomy by 12 months. Mean visual acuity letter score at 12 months was 72.7 ± 12.3 in the ranibizumab group and 75.1 ± 10.1 in the placebo group. Safety was similar across groups.CONCLUSION: Intravitreal ranibizumab may reduce the likelihood of proceeding to vitrectomy in patients with persistent, dense diabetic vitreous haemorrhage. Further studies appear feasible and justified.

AB - PURPOSE: To determine the feasibility of a definitive study of intravitreal ranibizumab to promote the clearance of persistent diabetic vitreous haemorrhage and thereby avoid vitrectomy.METHODS: This randomised, double-masked, placebo-controlled feasibility study recruited 24 participants with persistent diabetic vitreous haemorrhage listed for pars plana vitrectomy. Participants were randomised to a single 0.5-mg intravitreal ranibizumab injection or a single subconjunctival saline injection. The primary outcome measure was the number of participants requiring pars plana vitrectomy at week 7.RESULTS: Eight of 12 participants (66.7%) in the ranibizumab group required vitrectomy at week 7 versus 12 of 12 (100%) in the placebo group (absolute risk reduction 33.3%, 95% confidence interval 2.1-70.7%; p = 0.09). One additional eye in the ranibizumab group required vitrectomy by 12 months. Mean visual acuity letter score at 12 months was 72.7 ± 12.3 in the ranibizumab group and 75.1 ± 10.1 in the placebo group. Safety was similar across groups.CONCLUSION: Intravitreal ranibizumab may reduce the likelihood of proceeding to vitrectomy in patients with persistent, dense diabetic vitreous haemorrhage. Further studies appear feasible and justified.

KW - diabetic vitreous haemorrhage

KW - ranibizumab

KW - vitrectomy

UR - http://www.scopus.com/inward/record.url?scp=85074696042&partnerID=8YFLogxK

U2 - 10.1111/aos.14282

DO - 10.1111/aos.14282

M3 - Article

C2 - 31674134

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454